Ad26 EBOV vaccine

Drug Profile

Ad26 EBOV vaccine

Alternative Names: Ad26 EBOV vaccine - Crucell/NIH; Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV - Crucell/NIH; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Developer Bavarian Nordic; Crucell; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 29 Sep 2017 Johnson and Johnson receives a grant from Biomedical Advanced Research and Development Authority for Ad26 EBOV vaccine development in Ebola virus infections
  • 08 May 2017 Janssen completes a phase I trial in Ebola virus infections (Prevention) in USA (IM) (NCT02325050)
  • 02 May 2017 The University of Oxford initiates enrolment in the phase I extension PRISM trial for Ebola virus infections (Prevention, Combination therapy) in United Kingdom (NCT03140774)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top